European Archives - Page 674 of 1228 - European Medical Journal

Hematology 9.1 Journal feature image

Von Willebrand Factor and ADAMTS13 in COVID-19 and Beyond

von Willebrand factor (VWF) is a large, adhesive, multimeric protein involved in haemostasis. The larger the size (or number of VWF multimers), the greater the functionality of the protein.

Hematology 9.1 Journal feature image

Determination of Cut-Off Optimal Values of Ten Haematological Formulas in the Distinction Between Iron Deficiency Anaemia and β-Thalassaemia Minor

Anaemia is a public health problem. Two aetiologies of microcytic anaemia are relatively common in Tunisia: iron deficiency anaemia (IDA)…

EHA-ESMO Guidelines for the Diagnosis, Treatment, and Follow-up of Multiple Myeloma

EHA-ESMO Guidelines for the Diagnosis, Treatment, and Follow-up of Multiple Myeloma

ON DAY 6 of the European Hematology Association (EHA) Virtual Congress 2021, Pieter Sonneveld, Professor of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands, chaired the European Society for Medical Oncology and EHA (ESMO-EHA) joint session on clinical practice guidelines for the diagnosis, treatment, and follow-up of multiple myeloma.

Antibody Levels in COVID-19 Affected by Age, Gender, and Disease

Antibody Levels in COVID-19 Affected by Age, Gender, and Disease

AT THE EUROPEAN Hematology Association (EHA) 2021 Virtual Congress, Evangelos Terpos, University of Athens School of Medicine, Greece, discussed COVID-19 and how neutralising antibody levels are affected by various factors such as age, gender, and disease.

Hematology 9.1 Journal feature image

Allogeneic Peripheral Blood Stem Cell Transplantation in 34 Patients with Myelodysplastic Syndrome

Myelodysplastic syndromes (MDS) are clonal haematopoietic disorders of pluripotent stem cells, characterised by ineffective haematopoiesis…

Management of Multiple Myeloma in Older Patients

Multiple myeloma is a haematological malignancy predominantly affecting older people and has a median age of onset of 70 years.

Current and Future Therapies for β-Thalassaemia: A Review Article

β-thalassaemias are a clinically heterogenous group of inherited disorders caused by >200 described mutations in the β-globin gene, leading to a decreased or absent production of the β-globin chain.

Hematology 9.1 Journal feature image

Recurrent Episodes of Angioedema Consistent with Polycythaemia Vera

Polycythaemia vera (PV) is a condition characterised by an increasing number of the red blood cells in the blood.

Hematology 9.1 Journal feature image

Glanzmann Thrombasthenia: A Case Report

Eduard Glanzmann first reported Glanzmann thrombasthenia (GT) in 1918 after he identified a functional abnormality of platelets with defective clot retraction.

Webinar: Treatment of Heart Failure in 2021: moving towards personalized approach?

This webinar dives into the treatment of heart failure in 2021. Chaired by Dr. Jonathan Sackier, it features presentations from a panel of renowned experts.